Clinical Trial Update: MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

View source ↗

Summary

A clinical trial update for MSCAN evaluating ctDNA methylation as a prognostic and theranostic tool in pancreatic cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Yingbin Liu, MD, PhD, FACS | Conditions: Pancreatic Neoplasm, Pancreas Cancer | Status: RECRUITING